ACCD / CORRECTING and REPLACING -- Accolade To Present at Upcoming Investor Conferences

Accolade (ACCD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong more_horizontal

Accolade (ACCD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong more_horizontal

While Accolade increased revenue year over year, it is still losing money. Several analysts downgraded their price targets for the stock. more_horizontal

Accolade, Inc. (NASDAQ:ACCD ) Q2 2024 Earnings Conference Call October 4, 2023 4:30 PM ET Company Participants Todd Friedman - Senior Vice President, more_horizontal

Accolade (ACCD) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0. more_horizontal

Accolade is in a good position to meet its revenue growth guidance for both the current fiscal year and long term. There is a risk that ACCD's bottom more_horizontal

SEATTLE, Sept. 06, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Sept. 5, 2023 by Accolade, Inc. (NASDAQ: ACCD), please note more_horizontal

Accolade is experiencing strong demand due to rising healthcare costs and employers seeking ways to reduce expenses. The company's proprietary technol more_horizontal